

Chronic Illnesses III

Management of Patients on Dialysis

Learning Objectives

1. Design an appropriate anemia treatment plan for a patient receiving dialysis.
2. Develop an appropriate target hemoglobin range in patients receiving dialysis using the most recent literature on chronic kidney disease (CKD).
3. Determine the most appropriate phosphate-binding medication for a patient on dialysis.
4. Evaluate the role of cinacalcet in the treatment of hyperparathyroidism in patients with CKD on dialysis.
5. Demonstrate an understanding of the roles of both native and active vitamin D in patients on dialysis.
6. Distinguish the role of FGF23 (fibroblast growth factor 23) in the pathophysiology of secondary hyperparathyroidism.

Long-term Management After Kidney Transplantation

Learning Objectives

1. Distinguish the mechanisms of action, adverse reaction and drug-drug interaction profiles, and recommended monitoring principles for maintenance immunosuppressive agents.
2. Assess the risks of acute rejection and antibody-mediated rejection for the individual patient and evaluate treatment strategies.
3. Design appropriate therapeutic regimens for preventing and managing infectious cardiovascular and endocrine complications after transplantation.
4. Evaluate for the risk of malignancies after kidney transplantation, and compose treatment options for one of these complications.
5. Justify the importance of immunosuppressive drug adherence in transplantation, and demonstrate ways to predict and prevent nonadherence.

Biologic Therapies for Gastrointestinal Diseases

Learning Objectives

1. Design evidence-based treatment regimens for the management of gastrointestinal disease, especially inflammatory bowel disease.
2. Distinguish the role of biologic therapies, including safety concerns, in the treatment of inflammatory bowel disease
3. Evaluate appropriate treatment recommendations with health care providers regarding the use of biologic therapies in inflammatory bowel disease

4. Justify important drug education with patients regarding the use of biologic therapies in the treatment of inflammatory bowel disease